Abstract
People with HIV (human immunodeficiency virus) are at higher risk of developing Lymphomas in comparison to people without HIV. The risk of developing lymphomas in patients with HIV continues to persist, even in the HAART era. We retrospectively analysed outcomes of patients with HIV associated lymphomas between Jan 2012 and Oct 2022, with minimum follow up of 6 months. Outcomes have been reported in terms of overall response rate (ORR), overall survival (OS) and event free survival (EFS). Statistical methods such as Kaplan Meier test were used to assess the overall survival and progression free survival, while chi-square test was used to assess factors affecting disease response. Twenty-three patients were identified as HIV associated lymphoma in that duration. Four patients were excluded from the cohort due to insufficient data in the database record. 12 (63.15%) were male and 07 (36.85%) were females with male: female ratio of 1.7:1. Median age was 42 years ranging from 21 to 66 years. 11 (57.9%) patients had stage-4 disease at presentation. Median CD4 counts at diagnosis was 615/µl, ranging from 130 to 1100/µl. DLBCL cases were in majority which showed 60% of CR post 1st line Chemotherapy. At the last follow-up, 04 (21.05%) patients were dead and 15 (78.95%) patients were alive. 10 years Overall survival [OS] and Progression Free Survival [PFS] was found to be 78.95% ± 11 at a median follow up of 42.6 months ranging (1.7–114.3) months. HIV associated lymphomas have an acceptable prognosis, despite majority presenting with stage 4 disease, low median CD4 count at diagnosis, concomitant ART, and treatment with intensive chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
References
http://naco.gov.in/surveillance-epidemiology-0 Accessed on Nov 2022
Biggar RJ, Rosenberg PS, Cote T (1996) Kaposi’s sarcoma and non-Hodgkin’s lymphoma following the diagnosis of AIDS. Multistate AIDS/cancer match study group. Int J Cancer 68:754–758
Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, Grigg R, Hylton T, Pawlish KS, McNeel TS, Goedert JJ (2008) Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123:187–194
Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA (2014) Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS 28(15):2313–2318
Silverberg MJ, Lau B, Achenbach CJ et al (2015) North American AIDS cohort collaboration on research and design of the international epidemiologic databases to evaluate AIDS. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med 163(7):507–518
Noy A (2019) Optimizing treatment of HIV-associated lymphoma. Blood 134(17):1385–1394. https://doi.org/10.1182/blood-2018-01-791400
International Collaboration on HIV and Cancer (2000) Highlyactive antiretroviral therapy and incidence of cancer inhuman immunodeficiency virus-infected adults. J Natl Cancer Inst 92:1823–1830
Diamond C, Taylor TH, Im T, Anton-Culver H (2006) Presentation and outcomes of systemic non-Hodgkin′s lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma 47:182
Mounier N, Spina M, Gabarre J, Raphael M, Rizzardini G, Golfier JB et al (2006) AIDS-related non-hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 107:3832–3840
Cabrera ME, Silva G, Soto A, Roselló R, Castro C, Martínez V et al (2012) HIV-related lymphoma in a public hospital in Chile. Analysis of 55 cases. Rev Med Chile 140:243–50
Sampath R, Manipadam MT, Nair S, Viswabandya A, Zachariah A (2019) HIV-associated lymphoma: a 5-year clinicopathologic study from India. Indian J Pathol Microbiol 62(1):73
Rudresha AH, Khandare PA, Lokanatha D, Linu AJ, Babu MS, Lokesh KN, Rajeev LK, Smitha CS, Amale VB, Premalata CS, Nikita M (2019) HIV/AIDS-related lymphoma: perspective from a regional cancer center in India. Blood Res 54(3):181–188
Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, Burkholder GA, Reid EG, Rodriguez B, Deeks SG, Mayer KH, Moore RD, Kitahata MM, Eron JJ, Richards KL (2013) Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst 105(16):1221–1229. https://doi.org/10.1093/jnci/djt158
Acknowledgements
We thank all the members, and staff of Rajiv Gandhi Cancer Institute and Research Centre, India for their contribution in the conduct of the study.
Funding
No financial support was taken.
Author information
Authors and Affiliations
Contributions
Conceived and designed the study Dinesh and Narendra; Collected the data-Reema, Jyotsna and Nisha; Contributed data or analysis tools-Reema, Narendra; Performed the analysis-Reema, Sujay; Wrote the paper- Reema, Reviewed and corrected the final Draft- Dinesh, Rayaz, Narendra, Rohan, Pritish.
Corresponding author
Ethics declarations
Conflict of interest
All authors have no conflict of interest.
Consent Publish
Patient Permission to publish the data has been taken from the patient.
Ethical Approval
The study has been approved by the Institutional Review Board of our Centre.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Singh, R., Kapoor, J., Panwar, N. et al. HIV Associated Lymphomas: A Double-Edged Sword. Indian J Hematol Blood Transfus 40, 146–149 (2024). https://doi.org/10.1007/s12288-023-01636-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-023-01636-3